◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ALT

Altimmune Inc (ALT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-25

Altimmune Inc (ALT) operates in the BIOTECHNOLOGY industry and is headquartered in Gaithersburg, United States with about 57 employees. Its market capitalization is roughly $397 million. In the fiscal year ended 2025-12-31, ALT reported $0M in revenue and ($88M) in net income.

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.

Interactive charts & full statements → Open the ALT valuation workbench →

ALT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$0M	$0M	$0M	$0M	$0M	$4M	$8M	$6M	$10M	$0M	$5M	$11M	$10M	$18M	$25M	$24M	$21M	$28M	$33M	$15M	$2M
Gross Profit	($15M)	$0M	$0M	$0M	$0M	$4M	($25M)	$6M	($8M)	($18M)	($2M)	$6M	$6M	$18M	$25M	$24M	$21M	$28M	$33M	$15M	$2M
Gross Margin %	-48306.5%	100.0%	100.0%	100.0%	100.0%	100.0%	-309.4%	100.0%	-78.7%	-44249.4%	-38.1%	52.4%	58.1%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($100M)	($94M)	($103M)	($96M)	($88M)	($97M)	($55M)	($21M)	($43M)	($52M)	($11M)	($3M)	($10M)	($11M)	($6M)	($12M)	($24M)	($26M)	($35M)	($17M)	$1M
Operating Margin %	-323306.5%	-230461.0%	-515860.0%	-22518.5%	129029.4%	-2197.6%	-669.5%	-370.0%	-414.6%	-125401.2%	-215.4%	-32.0%	-100.0%	-60.5%	-24.9%	-48.3%	-112.2%	-94.3%	-107.1%	-112.7%	65.1%
Net Income	($92M)	($88M)	($95M)	($88M)	($85M)	($97M)	($49M)	($21M)	($39M)	($46M)	$194M	($3M)	($10M)	($12M)	($5M)	($4M)	($35M)	($32M)	($36M)	($14M)	$1M
Net Margin %	-296000.0%	-214861.0%	-475295.0%	-20762.2%	124577.9%	-2201.6%	-599.2%	-353.7%	-379.2%	-111860.3%	3706.4%	-32.3%	-97.7%	-65.4%	-19.5%	-15.7%	-166.0%	-117.2%	-110.7%	-92.8%	55.0%
EBITDA	($93M)	($87M)	($95M)	($88M)	($84M)	($97M)	($38M)	($20M)	($45M)	($52M)	($11M)	($3M)	($10M)	($11M)	($4M)	($3M)	($23M)	($29M)	($33M)	($16M)	$1M
Earnings Per Share (EPS)	$-0.50	$-1.00	$-1.34	$-1.66	$-1.81	$-2.35	$-1.91	$-1.56	$-13.98	$-108.77	$841.45	$-16.13	$-51.91	$-69.40	$-30.55	$-24.07	$-323.59	$-351.19	$-476.15	$-431.69	$21.71
Shares Outstanding (M)	185M	88M	71M	53M	47M	41M	26M	13M	3M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	$0M	$0M	$0M	($15M)	$0M	$0M	$0M	$0M
Gross Margin %	—	—	100.0%	-299100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($26M)	($24M)	($29M)	($21M)	($23M)	($22M)	($25M)	($25M)
Operating Margin %	—	—	-111126.9%	-417180.0%	-458440.0%	-436300.0%	-497320.0%	-495340.0%
Net Income	($23M)	($23M)	($27M)	($19M)	($22M)	($20M)	($23M)	($23M)
Net Margin %	—	—	-105223.1%	-380280.0%	-442920.0%	-391500.0%	-463600.0%	-456900.0%
EBITDA	($26M)	($21M)	($26M)	($18M)	($22M)	($20M)	($23M)	($23M)
Earnings Per Share (EPS)	$-0.12	$-0.18	$-0.27	$-0.21	$-0.27	$-0.26	$-0.33	$-0.32
Shares Outstanding (M)	185M	124M	101M	89M	81M	76M	71M	71M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($77M)	($68M)	($80M)	($76M)	($63M)	($78M)	($34M)	($10M)	($9M)	($20M)	$202M	($3M)	($8M)	($7M)	($2M)	($8M)	($15M)	($28M)	($13M)	($14M)	$2M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$12M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$1M	$0M
Free Cash Flow (FCF)	($77M)	($68M)	($80M)	($76M)	($63M)	($91M)	($35M)	($10M)	($10M)	($20M)	$201M	($3M)	($9M)	($7M)	($2M)	($8M)	($15M)	($29M)	($14M)	($15M)	$2M
FCF Margin %	-246974.2%	-164746.3%	-399240.0%	-17806.8%	92223.5%	-2053.3%	-424.9%	-166.0%	-100.7%	-49105.9%	3852.2%	-31.0%	-84.1%	-40.5%	-9.2%	-32.5%	-72.6%	-105.9%	-41.6%	-99.2%	82.7%
Dividends Paid	—	—	—	—	—	—	$135M	$3.8B	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($24M)	($21M)	($19M)	($12M)	($19M)	($17M)	($18M)	($27M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($24M)	($21M)	($19M)	($12M)	($19M)	($17M)	($18M)	($27M)
FCF Margin %	—	—	-74803.9%	-237940.0%	-387200.0%	-336800.0%	-365300.0%	-542360.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$527M	$280M	$139M	$211M	$207M	$219M	$245M	$54M	$55M	$63M	$225M	$20M	$22M	$17M	$23M	$23M	$27M	$34M	$56M	$67M	$72M
Cash & Cash Equivalents	$63M	$44M	$37M	$135M	$111M	$190M	$116M	$9M	$34M	$9M	$154M	$16M	$19M	$10M	$13M	$11M	$12M	$3M	$20M	$41M	$1M
Total Liabilities	$53M	$55M	$16M	$17M	$22M	$20M	$19M	$9M	$6M	$14M	$205M	$3M	$4M	$10M	$11M	$7M	$15M	$32M	$37M	$26M	$15M
Total Debt (Short + Long-Term)	$35M	$35M	$0M	$0M	$0M	$2M	$2M	$2M	$2M	$5M	$2M	$1M	$1M	$3M	$4M	$0M	$0M	$0M	$17M	$4M	$0M
Total Shareholders' Equity	$474M	$225M	$124M	$194M	$185M	$199M	$226M	$46M	$48M	$49M	$19M	$17M	$18M	$7M	$12M	$16M	$12M	$2M	$19M	$41M	$57M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALT viewer.

Other Companies in BIOTECHNOLOGY

PROK · ProKidney Corp. — $427 million
CCCC · C4 Therapeutics Inc — $415 million
ASMB · Assembly Biosciences Inc — $410 million
ALLO · Allogene Therapeutics Inc — $408 million
ZURA · Zura Bio Limited Class A Ordinary Shares — $389 million
TECX · Tectonic Therapeutic, Inc. — $387 million
RLMD · Relmada Therapeutics Inc — $382 million
MPLT · MapLight Therapeutics, Inc. Common Stock — $378 million

← ALSN All “A” companies ALTA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.